PTC Therapeutics (NASDAQ: PTCT) reported Q4 EPS of ($0.84), $0.02 better than the analyst estimate of ($0.86). Revenue for the quarter came in at $12.7 million versus the consensus estimate of $7.99 million.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.